Objects
Hersey, Peter, Nguyen, T., Farrelly, M., Menzies, S.W., Hirst, D., Johnson, H., Coventry, B., Collins, S.. Springer-Verlag; 2005. Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma.
Guo, S. T., Chi, M. N., Yan, X. G., Farrelly, M., Wang, F. H., Lai, F., Wang, J. F., Li, Y. P., Ackland, S., Scott, R., Agoulnik, I. U., Hondermarck, H., Yang, R. H., Thorne, R. F., Liu, T., Zhang, X. D., Jiang, C. C., Guo, X. Y., Zan, L. K., Wang, C. Y., Xi, Y. F., Jin, L., Croft, A., Tseng, H.-Y.. Nature Publishing Group; 2016. INPP4B is an oncogenic regulator in human colon cancer.
Lai, F., Guo, S. T., Norman, J., Liu, T., Hersey, P., Zhang, X. D., Jin, L., Jiang, C. C., Wang, C. Y., Croft, A., Chi, M. N., Tseng, H-Y., Farrelly, M., Atmadibrata, B.. Nature Publishing Group; 2013. Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3.
Shafren, D. R., Farrelly, M., Croft, A. J., Davies, B., Stewart, J., Ingham, R., Quah, M. Y., Au, G., Hersey, P.. Wiley-Blackwell Publishing; 2011. CAVATAK (Coxsackievirus A21) displays potent oncolytic activity in BRAFV600E mutant melanoma cells resistant to selective BRAF kinase inhibitors.